Kyndryl Holdings Inc vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Kyndryl Holdings Inc trades at $11.75 (market cap $2.59B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.88 (market cap $25.27B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 9.8× Kyndryl Holdings Inc's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while Kyndryl Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kyndryl Holdings Inc for 36 Days and Royalty Pharma plc Class A Ordinary Shares for 1 Days on average.
| KD | RPRX | |
|---|---|---|
Market Cap | $2.59B | $25.27B |
Volume | 5,354,348 | 3,671,183 |
Sector | Technology | Health |
52-Week High | $29.76 | $63.96 |
52-Week Low | $10.59 | $35.44 |
Typical Hold Time | 36 Days | 1 Days |
Enterprise Value | $5.41B | $32.50B |
Dividend Yield | — | 1.66% |
Signals from Pluang's Aura AI — not financial advice
Kyndryl (KD) trades at $11.75, up 2.62% with bearish technical signals but improving fundamentals. The company reported positive net income of $252M in 2025 after years of losses, with revenue stabilizing around $15B. Recent news highlights AI initiatives including a new Dallas innovation lab and healthcare IT acquisition. Analyst consensus is mixed with 71% hold ratings but a $14.67 price target suggesting 25% upside potential.
KD shows fundamental improvement with profitability returning, though earnings misses and competitive pressures remain risks. The stock trades at reasonable valuations (P/S 0.18x) but faces execution challenges in its AI transformation. Institutional interest is building with recent purchases, but technical weakness suggests near-term consolidation likely before sustained upward movement.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →